FDA approval of a generic sugammadex sodium formulation; regulatory action does not report clinical trial efficacy or comparative outcomes.
Reported
Formulation 1 concentration500 mg/5 mL (100 mg/mL)
Formulation 2 concentration200 mg/2 mL (100 mg/mL)
Approval date2026-07-28